ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury

BACKGROUND: In contrast with various pre-clinical studies, recent clinical trials suggest that high dose erythropoietin (EPO) treatment following kidney transplantation does not improve short-term outcome and that it even increases the risk of thrombotic events. ARA290 is a non-erythropoietic EPO de...

Descripción completa

Detalles Bibliográficos
Autores principales: van Rijt, Willem G, Nieuwenhuijs-Moeke, Gertrude J, van Goor, Harry, Jespersen, Bente, Ottens, Petra J, Ploeg, Rutger J, Leuvenink, Henri GD
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567997/
https://www.ncbi.nlm.nih.gov/pubmed/23302512
http://dx.doi.org/10.1186/1479-5876-11-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567997/
https://www.ncbi.nlm.nih.gov/pubmed/23302512
http://dx.doi.org/10.1186/1479-5876-11-9

Ejemplares similares